Biocon Biologics Global plc (the "Issuer"), incorporated under the laws of the United Kingdom and being a subsidiary of Biocon Biologics UK Limited, which is a subsidiary of Biocon Biologics Limited ("Biocon Biologics") and a step-down subsidiary of the Biocon Limited (the "Company"), subject to market conditions and due exigencies, is proposing to offer senior secured notes (the "Notes"). A preliminary offering memorandum dated September 23, 2024 (the "Offering Memorandum") has been prepared which shall be made available to the prospective investors and shall be submitted with the Singapore Exchange Limited ("SGX"). The Notes shall not be offered or sold in India.
The Notes are proposed to be irrevocably and unconditionally guaranteed on behalf of the Issuer by, among others, Biocon Biologics, being a material subsidiary of the Company and secured by, among others, a pledge over certain shares held by Biocon Biologics in Biosimilars Newco. Limited, being a subsidiary of Biocon Biologics.
The pricing of the Notes, including the aggregate principal amount, the issue price and the interest rate, shall be determined in accordance with international market practices by the joint global coordinators and joint lead managers appointed by the Issuer.
Shares of Biocon Limited was last trading in BSE at Rs. 370.40 as compared to the previous close of Rs. 365.60. The total number of shares traded during the day was 248205 in over 4974 trades.
The stock hit an intraday high of Rs. 372.70 and intraday low of 363.70. The net turnover during the day was Rs. 91607717.00. |
